Objectives: The 2015 Workshop of the Society for Hematopathology/European Association for Haematopathology aimed to review B-cell proliferations of varied malignant potential associated with immunodeficiency.
lymphoproliferative disorders (polymorphic LPDs), the majority of which are B-cell proliferations driven by EpsteinBarr virus (EBV) that typically lack additional genetic alterations. Hyperplasias in the immunodeficiency setting form nondestructive masses, whereas polymorphic lymphoproliferative disorders cause destructive lesions that may mimic large B-cell or classical Hodgkin lymphomas (CHLs).
Two other entities included in the group of EBVpositive B-cell proliferations of variable malignant potential represent localized forms of immunodeficiency disordersnamely, mucocutaneous ulcer and large B-cell proliferations associated with chronic inflammation. Both lesions are EBV positive, present as well-circumscribed masses or proliferations within confined spaces, and typically occur in immunocompetent patients. Some parallels can be recognized between large B-cell proliferations associated with chronic inflammation and breast implant-associated anaplastic large cell lymphoma. Although they are thought to result from localized loss of host immune surveillance or chronic immune stimulation, their pathogenesis is poorly understood.
The 2015 Society for Hematopathology/European Association for Haematopathology Workshop on Immunodeficiency and Dysregulation received a total of 101 case submissions that were grouped into the following four categories to facilitate review by the expert panel members: (1) B-cell hyperplasias, (2) polymorphic B-lymphoproliferative disorders, (3) mucocutaneous ulcer, and (4) large B-cell proliferations associated with chronic inflammation. Similar lesions occurring in various immunodeficiency backgrounds were evaluated together to allow exploration of unifying themes and disease definitions.
Hyperplasias (Early or Nondestructive Lesions)
Hyperplasias in the immunodeficiency setting are mass-forming lesions characterized by preservation of the involved tissue architecture and lack of distinguishing features of lymphoma. In the posttransplant setting, they usually present at an earlier age than other types of immunodeficiency-associated LPDs and typically occur in children who are seronegative for EBV at the time of transplantation. Hyperplasias much more frequently involve lymph nodes, tonsils, and adenoids than other extranodal sites. They tend to regress spontaneously or with reduction of immunosuppression; rare exceptions with concurrent or subsequent development of aggressive lymphomas or a fatal clinical course have also been reported. 1 Since histologic features of hyperplasias in immunodeficiency settings are often nonspecific and indistinguishable from hyperplasias in immunocompetent hosts, other causes, including infectious and inflammatory etiologies, must be carefully excluded.
In the WHO 2008 classification, the term early lesions was used to refer to hyperplasias arising from B cells, but due to the ambiguity of the term early, they have been renamed nondestructive lesions in the WHO 2016 update. 1, 2 In the WHO framework, nondestructive lesions are classified as a posttransplant lymphoproliferative disorder (PTLD) . Guidelines for what terminology should be used in diagnostic settings other than solid organ or stem cell transplantation, however, have not been well established. In the interest of exploring common themes in the context of the workshop, we adopted the term hyperplasias to allow inclusion of similar lesions in all types of immunodeficiency-related settings. Three subtypes of nondestructive hyperplasias have been formally recognized in the WHO 2016 classification: follicular hyperplasia (FH), infectious mononucleosis-like hyperplasia (IMH), and plasmacytic hyperplasia (PH). IMH and PH in the posttransplant setting were already incorporated in earlier iterations of the WHO classification.
A total of 25 cases of B-cell hyperplasias were submitted to the workshop, with the majority (n ¼ 16) arising in the posttransplant setting. The remaining cases were associated with autoimmune/iatrogenic conditions (n ¼ 8) or with probable immune senescence related to aging (n ¼ 2). A summary of the types of hyperplasia associated with immunodeficiency that were submitted to the workshop is shown in Table 1 . Hyperplasias due to T-cell proliferations are not included in the WHO classification. The T-cell hyperplasias submitted to the workshop occurred primarily in the iatrogenic/autoimmune setting (n ¼ 3) or primary immunodeficiency setting (n ¼ 3) and are discussed in Session 4; an unusual hematogone hyperplasia associated with congenital phosphatidylinositol 3-kinase Cd activating kinase mutation is discussed in Session 5 of this report.
Follicular Hyperplasia
Hypertrophy of adenoids and tonsils following solid organ transplantation in children has long been recognized, together with the accompanying histologic findings of FH, usually presenting as florid follicular hyperplasia (FFH). [3] [4] [5] [6] Initial studies found no significant differences in histologic features, distribution of EBV, or B-cell clonality in adenotonsillar hypertrophy between PTLD and immunocompetent patients; an increased risk of developing more aggressive PTLD within a 5-year period was also not significantly increased. 3, 7 Later studies, however, have suggested that FH may represent a precursor lesion to PTLD. 5, 6 Similar to monomorphic and polymorphic PTLD, [8] [9] [10] [11] [12] several studies have raised the possibility of including FH as an immunodeficiency-related LPD; however, the lack of consistent oncogenic mutations or translocations in FH had not previously supported their inclusion. More recently, detailed cytogenetic analyses showed that a spectrum of clonal karyotypic abnormalities was demonstrable in PTLDs, including monomorphic PTLD (75%), polymorphic PTLD (33%), and FFH (11%). 13 The presence of cytogenetic abnormalities did not correlate with the type of PTLD, EBV infection, or clinical outcome measures and was detected in some cases where flow cytometry or polymerase chain reaction (PCR)-based studies did not demonstrate B-cell clonality. 13 A minority of patients with FFH subsequently developed more advanced forms of PTLD, typically after a long latency period. 14, 15 The presence of clonal karyotypic abnormalities, together with the development of more aggressive and better-defined LPDs associated with immunodeficiency, at least in a subset of cases, supports the inclusion of FH as an immunodeficiency-related LPD.
The histologic features of FH in immunodeficiency and in immunocompetent patients cannot be reliably distinguished in most cases without the presence of EBV, particularly given the nonspecific characteristics and the absence of architectural effacement. Therefore, a high index of suspicion is necessary to consider testing for EBV-encoded small RNAs (EBER) in the appropriate clinical context.
Fourteen cases of FH, EBVþ were submitted to the workshop and included eight cases of PTLD, four cases arising in an autoimmune/iatrogenic setting, and two cases of unknown etiology presumably related to advanced age (Table 1) . Among the eight PTLD cases, the patients ranged in age from 3 to 48 years, with a median age of 7 years. All patients had mass-forming lesions and showed enlargement of tonsils and adenoids in four cases, cervical lymphadenopathy in three cases, and generalized lymphadenopathy in one case. All biopsy specimens showed intact tissue architecture with prominent follicular hyperplasia and unremarkable interfollicular areas. All were EBERþ, and one of six cases tested was also latent membrane protein 1 (LMP1)þ. In addition, one of two cases tested showed the presence of a simple clonal immunoglobulin (IG) gene rearrangement. The distribution and number of EBERþ cells were variable and often localized to one or a few follicles with scant interfollicular EBERþ cells, as illustrated by case SH2015-123 (Drs Margolskee and Bhagat, Columbia University). This case was that of a 12-year-old boy, 8 years Among the remaining six cases of FH, EBVþ, four cases presented in the background of ulcerative colitis and primary sclerosing cholangitis (case SH2015-257), systemic lupus erythematosus (case SH2015-388), and dasatinib therapy (cases SH2015-219 and 330), whereas the cause was unknown in two cases and was presumed to be related to advanced age (case SH2015-214, 71 years and case SH2015-282, 65 years). Similar to FH in the posttransplant setting, all 11 cases were mass forming and showed FH with otherwise preserved tissue architecture. Four of six cases were EBERþ with a similar distribution of EBERþ cells localized primarily to one or more hyperplastic follicles; 2 of 3 cases showed positivity for LMP1, and both cases tested lacked EBV nuclear antigen 2 (EBNA2). In most of these cases, multiple lymph nodes were involved, including two cases that had widespread lymphadenopathy. Case SH2015-282 (Drs Soderquist and Frank, University of Pennsylvania) was that of a 65-year-old man with no known immunodeficiency who had multiple episodes of isolated lymphadenopathy at different sites occurring over a period of 5 years. Several lesions were biopsied over time and showed FH, EBVþ; all resolved spontaneously without treatment.
Two cases were excellent examples of a recently recognized variant of FH, EBVþ occurring in association with dasatinib therapy, an oral tyrosine-kinase inhibitor administered to patients with chronic-phase or refractory chronic myeloid leukemia. 17, 18 Nine cases of IMH were submitted to the workshop, including five that occurred in the posttransplant setting and four others in autoimmune/iatrogenic settings. The cases ranged in age from 3 to 61 years (median, 20 years). Eight of nine cases were associated with EBV (EBERþ). Among the PTLD cases, three had tonsillar/adenoid enlargement while the remaining two had widespread lymphadenopathy. The overall architecture was preserved in the involved lymph nodes and tonsils, and although some hyperplastic follicles were present in most cases, there was marked interfollicular expansion by a mixed infiltrate composed of immunoblasts, some of which resembled Hodgkin/ReedSternberg (HRS)-like cells, small T cells, and plasma cells. EBERþ cells showed a variable distribution and ranged from scattered to numerous interfollicular cells or involved both follicular and interfollicular compartments. EBV latency was also variable (one of four LMP1 positive; zero of Of the four non-PTLD patients who had IMH, three had a history of autoimmune disease treated with immunomodulatory therapies, whereas the fourth patient was placed on maintenance methotrexate following chemotherapy for B-lymphoblastic leukemia. Three patients had multiple sites of lymphadenopathy, whereas one patient had involvement of the adenoids, lungs, and the central nervous system (CNS). The histologic features and EBV involvement were similar to the cases of IMH arising in the posttransplant setting. None of the nine IMH cases were associated with concurrent or subsequent progression to more aggressive disease, although one case, which was associated with Still disease and demonstrated hemophagocytic lymphohistiocytosis, was fatal (case SH2015-456, Dr Gerbi, Detroit).
Of relevance is the difficulty of identifying an etiologic factor in patients with multiple comorbidities: one case that exemplified this issue (case SH2015-163, Dr Daphne de Jong, Netherlands) was from a 20-year-old woman with complex autoimmune syndrome with minimal change nephropathy, anterior uveitis, Raynaud syndrome, arthralgia, and multiple sclerosis who had been treated with various immunosuppressive therapies, including steroids, cyclosporine, and an a-4 integrin antagonist (natalizumab). Given the longstanding autoimmune conditions and use of several iatrogenic agents, the IMH lesions in this patient posed a challenge for clinical management as the specific predisposing condition or agent could not be determined.
Separation of IMH from EBVþ mucocutaneous ulcer, polymorphic B-LPD, and CHL can be challenging. The distribution of lesions in mucosal and cutaneous sites, together with their circumscription, are the most salient features that allow the separation of mucocutaneous ulcer from IMH. Polymorphic B-LPDs, in contrast to IMH, are destructive lesions that exhibit a full range of B-cell maturation stages and typically harbor clonal B-cell gene rearrangements. Although CHL in immunodeficiency settings must fulfill criteria for the diagnosis of CHL and is generally associated with architectural effacement, its separation from IMH may be complicated because B-cell gene rearrangement studies are not informative in either diagnosis. In instances where architectural effacement may not be readily appreciable, such as in needle core biopsy specimens, distinguishing IMH from CHL, EBVþ may pose additional challenges. Similarly, separation from diffuse large B-cell lymphoma (DLBCL), EBVþ may be difficult when there is a T-cell/histiocyte-rich background and absence of sheets of EBV-positive large cells. Although Bcell receptor gene rearrangement studies are helpful to separate polymorphic B-LPDs and lymphomas from hyperplasias, limited B-cell repertoires in small biopsy specimens or in EBV-driven proliferations may yield spurious clones and further confound accurate diagnoses.
Plasmacytic Hyperplasia
PH is morphologically characterized by the predominance of plasma cells expanding the medullary cords and extending to involve the interfollicular regions. 1 Immunoblasts are generally infrequent, although follicular hyperplasia may be present. The plasma cells are polytypic and not expected to harbor B-cell receptor gene rearrangements. As in FH and IMH, most cases of PH involve the tonsils and adenoids of younger patients and are rarely associated with concurrent or subsequent polymorphic B-LPDs or lymphomas. Similar to FH, the histologic features are nonspecific, and the presence of EBV is imperative for the diagnosis. Two cases of PH, both occurring in the posttransplant setting, were submitted to the workshop. In contrast to the tonsillar/adenoid involvement reported in the literature, one patient had isolated lymphadenopathy, whereas the other had multifocal lymphadenopathy. Both cases showed interfollicular expansion by polytypic plasma cell proliferations, which were associated with EBV (EBERþ). Variable numbers of hyperplastic follicles were also present (case SH2015-328, Dr Bradley, Emory University). Neither of the workshop cases was associated with clonal proliferations or with progression of disease. PH lesions occurring in other immunodeficiency settings such as in the elderly have been reported 21 ; however, none were submitted to this workshop.
Two additional cases of EBV-negative, mass-forming lesions of polytypic plasma cell proliferations were submitted to the workshop. Case SH2015-467 (Dr Qayyum, Children's Hospital of Philadelphia) occurred in a 24-yearold woman with CVID who had three mass lesions involving the brain parenchyma. Case SH2015-248 (Dr Yohe, University of Minnesota) occurred in an inguinal lymph node of a 6-year-old male following hematopoietic stem cell transplant. As with EBV-negative FH, it was not possible to classify these latter two cases as PH associated with immunodeficiency. In summary, the cases of hyperplasias submitted to the workshop occurred in different types of immunodeficiency settings and shared several characteristic features. They typically formed mass lesions with nondestructive growth such that the involved tissue architecture was preserved. Clinical presentations were variable and included adenotonsillar enlargement that typically occurred in children in the posttransplant setting, isolated lymph node enlargement, involvement of multiple concurrent or metachronous nodal sites, or widespread lymphadenopathy. EBV involvement was also variable, with EBERþ cells typically focal and localized to one or a few hyperplastic follicles in FH to scattered or numerous EBERþ cells in the interfollicular areas in FH, IMH, and PH. The salient histologic features for the diagnosis of FH, IMH, and PH are summarized in Figure 1 . Association with EBV was an important feature to identify hyperplasias, particularly FH and PH, in immunodeficiency settings since other distinguishing histologic features were nonspecific. Separation from other reactive (infectious or inflammatory) causes of hyperplasia was not possible in the absence of EBV. As reported in the literature, most of the cases were self-limiting, although a small minority of cases had subsequent development of more aggressive lymphoproliferative disorders or lymphomas. Occasional simple clonal IG rearrangements or karyotypes were also identified, and although these features did not lead to a worse outcome, one case with hemophagocytic lymphohistiocytosis was fatal.
Polymorphic B-LPDs (Polymorphic PTLD and Polymorphic PTLD-Like Lesions in Other Immunodeficiency Settings) of the involved tissue site or cause destructive masses but do not fulfill criteria for the diagnosis of lymphoma. 1, 11, 13, 14, 22 They are classified in the posttransplant setting as polymorphic PTLD or P-PTLD but also occur in other immunodeficiency settings. P-PTLDs account for 20% to 80% of PTLDs and are the most common PTLDs in the pediatric age group. 23 We adopted the term polymorphic B-lymphoproliferative disorder in an effort to include P-PTLD as well as P-PTLD-like lesions in other immunodeficiency settings. Most polymorphic lesions are clonal proliferations driven by EBV that typically lack additional genetic alterations and regress in response to reduction in immunosuppression. They demonstrate variable proportions of B and T cells; B cells typically exhibit a full range of B-cell maturation stages from small-to medium-sized lymphocytes, plasma cells, and immunoblasts. The number and cytologic features of admixed immunoblasts may be variable and include atypical forms that mimic HRS-like cells. In some cases, T cells and histiocytes may predominate. Although polymorphic B-LPD almost always shows clonal B-cell receptor gene rearrangement, immunoglobulin light chain expression is often variable and ranges from polytypic to light chain-restricted B cells and plasma cells. Some lesions may show focal clonal proliferations or different light chain-restricted B cells and plasma cells in different portions of the same biopsy specimen. Simple karyotypic abnormalities may be demonstrable and have been reported in 15% to 30% of polymorphic B-LPDs. 12, 13 Given the morphologic and immunophenotypic spectrum of polymorphic B-LPD, defining the boundaries of this entity is often challenging. The differential diagnosis is therefore broad and not only encompasses nondestructive lesions such as hyperplasias, particularly IMH and EBVþ mucocutaneous ulcer, but also includes lymphomas such as CHL; plasmablastic lymphoma; lymphomatoid granulomatosis; large B-cell lymphomas, particularly T-cell and histiocyte-rich large B-cell lymphoma; and T-cell LPD/lymphoma, particularly angioimmunoblastic T-cell lymphoma. Polymorphic B-LPDs were the single largest category of cases submitted to the workshop and included 38 cases occurring in various immunodeficiency settings as summarized in Table 2 . Polymorphic B-LPDs occurring in the posttransplant and primary immunodeficiency settings were the most frequent (10 each), followed by autoimmune/iatrogenic settings (n ¼ 8), human immunodeficiency virus (HIV) (n ¼ 6), and an unknown cause presumably related to immune senescence (n ¼ 4). They affected all ages (1-90 years; median, 51 years). Unlike those reported in the literature, only five of 38 cases occurred in children. All except one case was associated with EBV, and an additional case showed multiple sites of involvement where EBV was present in one biopsied site but not the other. The clinical presentation ranged from isolated lymphadenopathy (n ¼ 7) to widespread lymphadenopathy with or without splenomegaly (n ¼ 7), as well as involvement of extranodal sites (n ¼ 21), including the lungs (n ¼ 6), CNS (n ¼ 5), and skin (n ¼ 2). Several patients demonstrated extensive systemic symptoms, and two were associated with hemophagocytic lymphohistiocytosis (HLH). Unlike reports in the literature, only 53% of polymorphic B-LPDs among the workshop cases showed IG gene rearrangements; occasional cases with small T-cell clones and simple clonal karyotypes were seen. Light chain expression was variable and polytypic in 58% of cases. Most patients required treatment, and a wide range of treatment options were employed, including withdrawal of immunosuppression, institution of antiretroviral therapy in patients with HIV, donorlymphocyte infusion, rituximab with or without a variety of chemotherapeutic agents and/or steroids, chemoradiotherapy, and hematopoietic stem cell transplantation. Clinical outcomes were also variable, with resolution of symptoms with withdrawal of immunosuppression to death due to dissemination of disease, multiorgan failure, and infectious complications in three cases.
The 10 P-PTLD cases occurred in the background of solid organ as well as hematopoietic stem cell transplantation and ranged in age from 1 to 62 years with a median age of 38 years. These lesions frequently followed primary EBV infection where the recipient was EBV negative at the time of transplantation. Lymph nodes were involved in three cases, both nodal and extranodal sites in one case, and extranodal sites in six cases, including lungs (n ¼ 4), CNS (n ¼ 1), colon (n ¼ 1), nasal polyp (n ¼ 1), bone (n ¼ 1), and liver/spleen (n ¼ 1).
Histologic features showed the presence of architectural destruction and a mixed infiltrate with full range of B-cell maturation stages represented, including immunoblasts, small-to medium-sized lymphoid cells, plasma cells, and variable numbers of reactive T cells. The immunoblasts were typically numerous and showed atypical forms and HRS-like morphology. The HRS-like cells were characterized by the expression of CD45, CD20/CD79a, CD30, PAX5, OCT2, and BOB1, as well as CD15 in a subset. In some cases, T cells were the predominant cell type within the infiltrate. EBER was positive in nine of 10 cases, whereas LMP1 (three of five) and EBNA2 (one of two) were positive in subsets of cases.
A typical example of polymorphic B-LPD was provided by case SH2015-13 (Dr Song, UCLA), which occurred in a 14-month-old boy after cardiac transplantation who had persistent fever, pancytopenia, rising EBV titers, and extensive lymphadenopathy in bilateral cervical, mediastinal, and left abdominal para-aortic regions as well as hematosplenomegaly. An excisional lymph node biopsy specimen and the bone marrow showed effacement by an extensive polymorphic infiltrate with numerous EBERþ immunoblasts. Flow cytometry identified a large B-cell proliferation lacking light chain expression. Both biopsy specimens demonstrated an identical clonal IG gene rearrangement, but no karyotypic or FISH abnormalities were detected. In addition, six of eight laboratory criteria for the diagnosis of HLH were met, including numerous bone marrow histiocytes that demonstrated hemophagocytosis. The patient was treated with reduction of immunosuppression, etoposide, and dexamethasone, with complete resolution of the P-PTLD.
Among the P-PTLDs, the mixed or polymorphous nature of the infiltrates resulted in varied appearances not only between cases but also in different biopsy specimens from the same patient as seen in case SH2015-133 (Dr Maietta, Montreal University) and within the same biopsy specimen (case SH2015-460, Dr Tousseyn, Leuven). Case SH2015-133 was from a 32-year-old man, 6 years after lung transplant who had polymorphic B-LPD in two separate sites: a nasal polyp characterized by a mixed infiltrate with prominent HRS-like cells and a small intestinal lesion with numerous immunoblasts but without prominent HRS-like morphology. In case SH2015-460, an inguinal lymph node in a 55-year-old patient after allogeneic hematopoietic stem cell transplant showed two distinct components: one resembling a polymorphous lesion with immunoblastic proliferation and HRS-like cells and the other a relatively monomorphic plasmablastic proliferation with brisk mitotic activity resembling a plasmablastic lymphoma. Both components were EBERþ.
Polymorphic B-LPDs are characterized by the presence of clonal IGH gene rearrangements. Among the workshop cases, three of five showed clonal IGH gene rearrangements; six of seven demonstrated at least focal light chain restriction, although some demonstrated different light chains in different portions of the biopsy specimen. One case showed a small T-cell gene rearrangement. None of the cases demonstrated a clonal karyotype. In six patients in whom clinical outcome was reported, four were alive with no evidence of disease, while another showed progressive disease despite rituximab treatment. One patient died of disseminated disease involving the colon, bone marrow, and multiorgan failure.
Ten cases of polymorphic B-LPDs occurred in the setting of primary immunodeficiency, including six patients with CVID and one each with dedicator of cytokinesis 8 (DOCK8) deficiency, Chediak-Higashi syndrome, X-linked lymphoproliferative syndrome, and Bloom syndrome. Clinicopathologic, histologic, and molecular features were similar to the spectrum presenting in the posttransplant setting with a median age of presentation of 26.5 years. Two of the five cases tested showed a clonal IGH rearrangement and light chain restriction, and one of three showed small Tcell clones and another showed an oligoclonal proliferation. One case showed a hyperdiploid karyotype. Treatment was highly variable, ranging from rituximab, chemotherapy, and hematopoietic stem cell transplant. Where available, outcomes usually showed resolution of the polymorphic B-LPD, although two patients subsequently developed CHL and DLBCL, both associated with EBV.
The eight polymorphic B-LPD cases occurring in autoimmune/iatrogenic settings displayed some similarities as well as differences from the P-PTLD group. The patients were typically older adults and ranged in age from 45 to 74 years with a median of 60.5 years. They arose most commonly (five of eight) in patients with rheumatoid arthritis treated with methotrexate or other similar immunosuppressive regimen. Similar to P-PTLD, they occurred in a single nodal site (three of five), multiple nodal sites (three of five), or extranodal sites such as the lung (two of five). IGH gene rearrangements were present in two of four cases and three cases each showed polytypic or light chain-restricted B and plasma cells. One case showed a clonal karyotypic abnormality.
Management of these lesions varied from withdrawal of immunosuppression to single-agent rituximab or in combination with cytoxan, steroids or immunochemotherapy, and hematopoietic stem cell transplant. Clinical outcome data were available for seven patients, of whom four achieved complete remission, two died of progressive disease, and another patient died of an unrelated cause (pancreatic carcinoma). Two cases exemplifying typical scenarios in the autoimmune/iatrogenic background were discussed in further detail. The first case was from a 61-year-old man with progressive anemia and fatigue who had multiple bilateral pulmonary nodules without lymphadenopathy or hepatosplenomegaly (case SH2015-408, Dr Perry, Manitoba). At age 19 years, he was diagnosed and treated for CHL with combination chemoradiation. He had a recurrence but again achieved complete response. His disease course was complicated by anthracycline-based cardiotoxicity and development of a polymorphic B-LPD, EBVþ for which rituxan monotherapy was planned, but the patient died of deteriorating cardiorespiratory function. The second case was from a 52-year-old woman with rheumatoid arthritis who was managed on an immunosuppressive regimen of methotrexate and tumor necrosis factor a (TNF-a) inhibitor (case SH2015-478, Drs Wu and Johnson, Stanford University). She developed multiple sites of lymphadenopathy associated with B symptoms, and a cervical lymph node demonstrated polymorphic B-LPD, EBVþ. The mixed lymphoid proliferation showed large atypical cells resembling HRS cells, and the differential diagnostic considerations included an EBVþ CHL as well as large B-cell lymphoma. Her symptoms presented 1 month after cessation of immunosuppression and eventually resolved completely.
In autoimmune diseases such as rheumatoid arthritis, disease severity by itself has been linked to the development of EBV-associated LPD and lymphoma. In addition, the duration of disease as well as the length of treatment with an immunosuppressive regimen such as methotrexate has also been associated with the development of immunodeficiency disorders. These proliferations can also arise after an interval of methotrexate withdrawal at the time of reintroduction of the drug, further complicating the management of such patients. Most cases in the literature are associated with rheumatoid arthritis and methotrexate; however, several autoimmune conditions as well as therapeutic agents such as TNF-a and integrin antagonists have been implicated in the genesis of the immunodeficiency-related spectrum of lymphoproliferations. [24] [25] [26] [27] [28] [29] [30] These cases of immunodeficiencyrelated polymorphic B-LPDs arising in autoimmune/ iatrogenic conditions submitted to the workshop underscored the need for a high index of suspicion to obtain additional clinical information in circumstances where the pathologist may not be made aware of prior treatment regimens or the treatment course and timing. Six cases of polymorphic B-LPDs occurred in the HIV/ AIDS setting and four additional cases in older individuals likely related to immune senescence. Clinicopathologic, histologic, and molecular features were similar to the spectrum presenting in posttransplant settings. Median ages of presentation included 35 years for HIV/AIDS and 75 years for those associated with immune senescence. Most cases tested showed a clonal IGH rearrangement, occasional small T-cell clones, and polytypic light chain expression patterns; none showed a clonal karyotype.
In contrast to the typical aggressive lymphomas that occur in patients with HIV/AIDS, such as primary effusion lymphoma, plasmablastic lymphoma, and large B-cell lymphoma arising in human herpesvirus 8 (HHV8)-associated MCD, six workshop cases showed polymorphic B-LPDs. Four of six patients had not been previously treated with highly active antiretroviral therapy (HAART) at the time of diagnosis of the polymorphic B-LPD, and another was on HAART but showed poor compliance. Four of six patients showed improvement or complete resolution of symptoms after initiation of HAART; another patient required R-CHOP (rituximab, cyclophosphamide, hydroxydaunorubicin, vincristine, prednisone) in addition to HAART and achieved complete remission. Image 2 illustrates a case of polymorphic B-LPD presenting as bilateral pulmonary nodules with radiologic features initially diagnosed as primary tuberculosis in a patient with HIV/AIDS who showed a dramatic response of the LPDs after initiation of HAART (case SH2015-83, Dr Goodlad, Edinburgh). 31 In summary, the cases of polymorphic B-LPDs submitted to the workshop showed a broad clinicopathologic spectrum, occurred in multiple different immunodeficiency settings, and elicited a broad differential diagnosis. Typical features included effacement and destructive growth in nodal or extranodal sites and a full spectrum of B-cell maturation stages admixed with abundant immunoblasts, often with HRS-like morphology and a mixed inflammatory infiltrate. These lesions raised the need to broaden differential diagnostic considerations as well as obtain additional ancillary studies, including quantitative immunoglobulin profiles, to confirm the possibility of immunodeficiency-associated polymorphic B-LPDs that may resolve with conservative management. Most patients required some form of clinical intervention, and a graded approach to management was found to be efficacious, with aggressive treatment regimens reserved for patients with refractory disease. Marked responses were observed in patients with autoimmune/iatrogenic immunosuppression after withdrawal of immunosuppressive agents and in patients with HIV/AIDS, in whom complete resolution was achieved after initiation of HAART. The HIV/AIDS examples of polymorphic B-LPDs underscored the need for a trial of conservative management in patients with lesions that mimic aggressive lymphomas such as CHL or large B-cell lymphoma in the background of immunosuppression. Polymorphic B-LPDs arising in autoimmune/iatrogenic conditions emphasized the need for a high index of suspicion to obtain clinical history of prior or current treatment regimens. Patients with underlying primary immunodeficiency may be at higher risk for developing additional immunodeficiency-related LPDs and thus must be monitored closely even if the initial polymorphic LPD has resolved.
EBV-Positive Mucocutaneous Ulcer
EBV-positive mucocutaneous ulcer was first described as an entity in 2011, although it is likely that descriptions of similar lesions were present in earlier or contemporaneous literature. [32] [33] [34] [35] Using our proposed nomenclature, this entity will be further referred to as mucocutaneous ulcer (MCU), EBVþ. The initial series included a majority of apparently immunocompetent but elderly individuals, patients receiving therapeutic immunosuppression for rheumatoid arthritis and other autoimmune disorders, and one allogeneic stem cell transplant recipient. 32 A small number of cases have subsequently been reported, including some after solid organ transplant. [36] [37] [38] [39] [40] In cases of iatrogenic immunosuppressionassociated MCU, EBVþ outside the transplant setting, methotrexate is the most commonly implicated drug, usually in the context of a connective tissue disorder such as rheumatoid arthritis, although associations with azothioprine and cyclosporine have also been documented. 32, 33, [35] [36] [37] 39, 40 MCU, EBVþ also appears to be one of the more common subtypes of EBV-associated lymphoproliferative disorder arising as a complication of methotrexate therapy, accounting for around 40% of cases. 37 Patients have well-circumscribed, often painful, ulcerating lesions arising at mucosal or cutaneous sites. Oropharyngeal
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Image 2 Polymorphic B-lymphoproliferative disorder in a patient with human immunodeficiency virus (HIV) (case SH2015-83). Initially diagnosed as primary tuberculosis, this polymorphic B-lymphoproliferative disorder presented as bilateral pulmonary nodules in a 40-year-old woman with HIV (A, x4). A polymorphous infiltrate with increased immunoblasts is seen in the lung biopsy specimen (B, x40), which shows expression of CD20 (C, x40) and CD30 (D, x40), mucosa is the most frequent site of presentation. 32, 34, 37 Cutaneous involvement is often perioral, but other acral sites or the trunk may be affected. Any part of the gastrointestinal tract may be involved, and patients occasionally have a variety of abdominal symptoms, including abdominal emergencies. 38 Importantly, and irrespective of site, no mass lesion is detectable on clinical examination or imaging. 38 The presence of systemic lymphadenopathy and/or splenomegaly should also lead to a presumptive diagnosis of MCU, EBVþ being questioned. Two cases with concomitant cervical lymphadenopathy local to MCU, EBVþ of the tonsil were included in the initial study, but as these were not examined microscopically, it is possible that the enlarged nodes were reactive in nature. 32 In addition, EBV-DNA is typically undetectable in peripheral blood, in contrast to many other types of EBV-associated lymphoproliferative disorders. 38 Biopsy specimens of MCU, EBVþ reveal circumscribed shallow ulcers, the base of which contains a polymorphous infiltrate comprising variable numbers of immunoblasts and large atypical Reed-Sternberg-like cells. These are admixed with small lymphocytes, plasma cells, histiocytes, and eosinophils. Plasmacytoid apoptotic cells are usually prominent, and there is vascular invasion with thrombosis and sometimes necrosis in a significant proportion. 32 The base of the lesion is sharply defined by a rim of small lymphocytes. In squamous mucosa and skin, there
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Image 2 (cont) Also shown are expression of polytypic j (E, x40) and k (F, x40) light chains. Radiographic images taken at initial presentation (G) and after initiation of highly active antiretroviral therapy (H) show dramatic improvement of the pulmonary infiltrates.
may be reactive epithelial atypia, and pseudoepitheliomatous hyperplasia is often present. 32, 38 The immunoblasts and
Reed-Sternberg-like cells are EBV-positive B-cells that are uniformly CD30 positive. A proportion show downregulation of CD20, but they express PAX5, MUM1, OCT2, and, usually, BOB1. 32, 38 A high prevalence of CD15 expression was reported in one study but was absent in another. 32, 38 Staining for EBV typically reveals a type II or type III latency pattern. 32, 37, 38 The background small lymphocytes and some activated cells are of T lineage, and antibodies to CD3 are useful in highlighting the constraining rim of T lymphocytes at the base and sides of each lesion. Monoclonal immunoglobulin gene rearrangement can be identified in around half of cases. 32, 34, 38 The pathogenesis of EBV-MCU is not fully established. In immunocompetent individuals, cytotoxic T cells act to keep EBV-induced B-cell proliferation in check and maintain the virus in a dormant state. A diminished T-cell repertoire is encountered in immunosuppressed patients, conferring a reduced ability to detect all EBV-associated antigens, with consequent proliferation of only restricted clones of EBV-specific T cells when the virus is encountered. In MCU, EBVþ, it is speculated that immune surveillance is reduced, either as a result of age-related immune senescence or iatrogenic immunosuppression, to a level that is only just sufficient to maintain the virus in a dormant state systemically. Exposure to an additional site-restricted immune-modulating factor is then believed to tip the balance toward a localized EBV-driven lymphoproliferation. 32 Sites at which EBVinfected cells are prevalent, such as Waldeyer's ring, may be particularly prone to this disruption in equilibrium. This hypothesis may also explain the high incidence of clonal and oligoclonal T-cell receptor gene rearrangements found in lesions of MCU, EBVþ. 34, [41] [42] [43] MCU, EBVþ is an indolent disease. Prior to the initial series, cases were often treated aggressively. However, in apparently immunocompetent elderly individuals, spontaneous regression appears to be the norm, while reduction in immunosuppression is sufficient for most patients receiving therapeutic immunosuppression. [32] [33] [34] [35] [36] 38, 40, 44 Most patients do not have a relapse, although occasional cases run a relapsing and remitting course without progression. 32 The differential diagnosis of MCU, EBVþ includes EBV-positive cases of polymorphic B-cell lymphoproliferative disorder, DLBCL, and CHL. The cytologic composition and phenotype of MCU, EBVþ is indistinguishable from polymorphic B-LPD in many cases and in some is identical to DLBCL, EBVþ. Clinical features are paramount in making the distinction, particularly the localized nature of MCU, EBVþ and absence of a mass lesion. Peripheral blood EBV-DNA load may also be useful, and a putative diagnosis of MCU, EBVþ should be questioned if elevated. 38 Pathologically, the sharp circumscription of MCU, EBVþ with a band of small T cells at the base of the lesion should help differentiate from the more infiltrative pattern seen with polymorphic B-cell lymphoproliferative disorders and EBV-positive DLBCLs. MCU, EBVþ may also resemble CHL, morphologically and phenotypically, with the Reed-Sternberg-like cells expressing CD30 and CD15. However, the clinical criteria described above, the extreme rarity of CHL presenting as extranodal disease in the absence of nodal involvement, and the presence of an intact B-cell program with CD45 expression in MCU, EBVþ should allow distinction.
A total of 17 cases submitted to the workshop Table 3 fulfilled criteria for MCU, EBVþ: five cases in apparently immune-competent individuals (cases SH2015-1, 72, 299, 344, and 422), eight in the context of non-transplant-related iatrogenic immunosuppression (cases SH2015-18, 106, 88, 153, 206, 252, 325, and 481), and three solid organ transplant recipients (cases SH2015-169, 335, and 501). Last, one unique case submitted by Dr Krishna (case SH2015-178) arose in the previously unreported context of congenital immune suppression, in a 16-year-old male patient with CHARGE syndrome (coloboma, heart defect, atresia of the nasal choanae, retardation of growth, genital and ear abnormalities, and deafness). MCU, EBVþ most likely arose in a background of age-related immune senescence in the first of these groups, with the median age of the patients being 74 years (range, 49-79 years). As with cases reported in the literature, iatrogenically immunosuppressed patients with connective tissue disorders were most commonly receiving methotrexate at the time of diagnosis (n ¼ 4). Other drugs included azathioprine, mycophenolate mofetil, and imatinib. Six cases involved the oral cavity, four included the skin (two on the face, one each arm and leg), and seven arose at various sites in the gastrointestinal tract, including stomach (n ¼ 2), small intestine (n ¼ 3), sigmoid colon (n ¼ 1), and anus (n ¼ 1). Quantification of peripheral blood DNA was undertaken in five patients (cases SH2015-1, 106, 153, 335, and 501), encompassing age-related, iatrogenic immunosuppression, and posttransplant settings. The result was negative in all cases.
Characteristic pathologic features, including the spectrum of morphologies that may be encountered, were well illustrated by certain cases Image 3 . Low-power view of cases SH2015-72 (Dr Dhesi) and SH2015-169 (Dr Nicolae) highlight the circumscribed nature of MCU, EBVþ and the presence of a confining band of small T cells at the base of the lesion. The case of Dr Dhesi was also an example of MCU, EBVþ with relatively few immunoblast and Reed-Sternberg-like cells, and it contrasted with that of Dr Grogg (SH2015-206), in which immunoblasts formed confluent sheets reminiscent of DLBCL. The case submitted by Dr Roden (SH2015-344) was a good example of MCU, EBVþ mimicking CHL, and an angiocentric and angiodestructive growth pattern was evident in some, best illustrated in case SH2015-153 (Dr Quintanilla-Fend). Two of five cases tested demonstrated clonal immunoglobulin gene rearrangement. Only two were examined for T-cell receptor rearrangement, and neither showed evidence of a clone. In most cases with available clinical information, the lesions resolved spontaneously or on reduction in immunosuppression, with or without the addition of rituximab. One case relapsed but resolved following reduction in immunosuppression plus rituximab (SH2015-88), and one case (SH2015-1) ran a relapsing and remitting course despite receiving rituximab but without progression.
Large B-Cell Proliferations Associated With Chronic Inflammation (DLBCL Associated With Chronic Inflammation)
In the WHO classification, DLBCL associated with chronic inflammation (DLBCL-CI) is defined as a lymphoid neoplasm occurring in the context of longstanding chronic inflammation, showing an association with EBV. 45 This entity emerged from descriptions of large B-cell lymphoma presenting in the pleural cavities of patients with longstanding pyothorax, the latter usually a consequence of therapeutically induced pneumothorax as a treatment for tuberculosis. [46] [47] [48] [49] [50] [51] Originally labeled as pyothorax-associated lymphoma (PAL), initial descriptions were in Japanese patients, but similar cases were subsequently reported in Western populations. [52] [53] [54] In the largest study to date, there was a mean latency period of 37 years (range, 20-60 years) between induced pneumothorax and diagnosis of PAL. 48 There is a striking male predominance despite chronic pyothorax being equally as prevalent in females, suggesting an increased susceptibility in men. Patients typically have pain, fever, respiratory symptoms, and a mass lesion in the pleural cavity. 48, 52 The pathology is that of DLBCL, typically with immunoblastic or plasmablastic morphology and a post-germinal center phenotype. Most cases are positive for EBV, usually with a type III latency pattern, and aberrant expression of T-cell antigens is not infrequent. 47, 48, 52, 55 Most cases are localized at presentation but despite this, and irrespective of treatment modality, run an aggressive clinical course with median survivals of less than 1 year and a 5-year overall survival of around 20% quoted. 48, 52 The concept of EBV-associated DLBCL arising on a background of chronic suppurative inflammation was subsequently extended to include cases arising in association with chronic osteomyelitis, venous ulcers, and metallic joint prostheses and surgical mesh implants. [56] [57] [58] As with PAL, these cases displayed a long latency period between the onset of inflammation and development of lymphoma and a marked male predominance, although the case numbers are too few to comment on treatment and outcome. Nevertheless, such cases are included under the more generic name of DLBCL associated with chronic inflammation currently employed in the WHO classification.
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More recently, a group of neoplasms has been described that shares some features with previously documented cases of DLBCL-CI and is sometimes appended this moniker but differs in several respects. All constitute stage IE EBVpositive large B-cell proliferations that appear to arise in confined spaces in association with fibrin, either in the form of thrombus or in cystic lesions showing evidence of previous hemorrhage with organization. The initial cases were reported as incidental findings in the cardiovascular system in association with aortic grafts, atrial thrombus, atrial myxoma, or replacement heart valves. [59] [60] [61] [62] [63] [64] Other cases have been described in the inner linings of cystic lesions, including splenic pseudocyst, renal cyst, adrenal pseudocyst, hydrocele, testicular pseudocyst, and cystic ovarian teratoma. [65] [66] [67] [68] No mass lesion is found. Instead, microscopic aggregates of large B cells are seen lying within thrombus or in amorphous fibrinous material showing signs of previous hemorrhage, the latter lining cyst walls or lying close to the surface of atrial myxoma. [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] The large B-cell proliferations are clonal, typically have a post-germinal center phenotype, and are almost always EBV positive. A type III latency pattern is most frequently seen. 59, 65 In contrast to PAL, as well as the absence of a mass lesion, no suppurative inflammation is seen and the outcome appears to be excellent. All the reported cases with follow-up were either alive with no evidence of disease or were in complete remission when they died of unrelated causes. [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] Although many of the patients were treated with adriamycin-containing regimens, some were managed to equally good effect with surgery alone or single-agent rituximab, suggesting that aggressive chemotherapy may represent overtreatment. 60, [64] [65] [66] These differences have led some authors to propose that these lymphoproliferations should be regarded separately from the prototypic DLBCL-CI, PAL and alternative names have been suggested to emphasize their more indolent behavior and unique pathologic features. These include fibrin-associated large B-cell lymphoma, microscopic DLBCL, and cystic DLBCL. 59, 66, 68 However, a solitary report of a case involving a subdural hematoma with an invasive lymphoma in the adjacent brain questions the assumption that benign behavior is guaranteed, although there is no clear documentation of progression of an initial microscopic lymphoma to the invasive component. 69 This, coupled with the small number of cases studied to date, makes it difficult to draw definite conclusions as to the relatively benign behavior of these lesions. Therefore, it is likely that they will be retained in the category of DLBCL-CI in the upcoming revision of the WHO classification but separated under the heading "incidental DLBCL associated with chronic inflammation." The Workshop Review Panel, however, preferred the term large B-cell proliferations associated with chronic inflammation (LBP-CI), in recognition of the variable clinical course exhibited by these lesions. The pathogenetic mechanisms of large B-cell proliferations associated with chronic inflammation are not fully elucidated, but there is evidence to suggest that in pyothorax-associated lymphomas, as well as the more indolent group of lymphoproliferations, longstanding inflammation in an enclosed space results in accumulation of cytokines such as interleukin (IL)-6 and IL-10. The former is thought to enhance the growth of EBV-infected B cells that have escaped host immune surveillance as a consequence of the latter. 70, 71 The differential diagnosis of LBP-CI includes EBVpositive DLBCL (of the elderly), with which it shares many features, including a post-germinal center phenotype, a type III latency pattern, and a propensity to occur in the elderly. 72, 73 However, LBP-CI is localized at presentation and associated with an underlying lesion of long standing, be it chronic pyothorax, atrial myxoma, mural thrombus, or cyst. DLBCL-CI arising in the pleural cavity differs from primary effusion lymphoma (PEL) in lacking HHV8 and a history of immune suppression. 74 Also, cases conforming to descriptions of PAL have mass lesions, which is not the case for PEL. Lymphomatoid granulomatosis differs from DLBCL-CI in showing multifocal involvement of lung parenchyma in most cases, together with numerous background small T cells. 75 Five cases were submitted to the workshop under the heading of DLBCL-CI (SH2015-68, 147, 176, 470, and 471). There were no cases of PAL, with all five conforming to the pattern of LBP-CI described above. Two cases were associated with atrial myxoma, two had mural thrombus (one intra-atrial and one within an aortic aneurysm), and one case arose within a renal cyst. The cases of Dr Graces (SH2015-68) and Dr Ruano (SH2015-470 and SH2015-471) illustrate this spectrum of presentation and the characteristic pathologic features Image 4 . As with similar cases reported in the literature, these lymphoproliferations comprised microscopic collections of EBV-positive large B cells with a post-germinal center phenotype and usually a type III latency pattern. The clinicopathologic features are summarized in Table 4 along with details of previously reported cases. They are localized non-mass-forming lesions that typically do not progress. Two cases with follow-up were treated with R-CHOP and had long-term remission. However, as illustrated in SH2015-147 submitted by Dr Rogeny, although excision alone may result in complete remission, local recurrence remains a possibility. In addition, the associated thrombus in this case seems to have been partly or wholly responsible for the patient's demise.
Conclusions
The cases submitted to the workshop clearly demonstrated that EBV-positive proliferations of varied malignant potential, as defined in the introduction to this section, may occur in a variety of different settings associated with an altered immune state. Thus, cases categorized as hyperplasias; polymorphic LPDs; MCU, EBVþ; and LBP-CI were encountered in posttransplant patients, as well as in association with iatrogenic immune suppression (usually in patients with autoimmune disease), congenital immune deficiency and HIV infection, and as a presumed consequence of immune senescence in elderly individuals. Moreover, in many instances, the biology of morphologically similar proliferations appeared to be similar, irrespective of the clinical scenario in which they were encountered, the latter being most important in dictating how best to therapeutically restore immunity to as near normal as possible. Although more study is required to determine if this is truly the case, some general comments of practical use can be made. For hyperplasias and polymorphic LPDs, a graded approach to treatment is recommended, ranging from observation, to reduction in immunosuppression (reduced dose of immunosuppressive agents or introduction of HAART in HIV), to single-agent B C D A rituximab, to rituximab plus multiagent chemotherapy. The initial starting point on this scale of treatment is determined by a number of factors, including the pathologic findings (eg, most cases of hyperplasia spontaneously resolve), the practicality of reducing immunosuppression (eg, balancing the risk to a transplanted organ with the risk of progression to an aggressive lymphoproliferation), and the clinical extent and apparent aggressiveness of the disease at presentation. For MCU, EBVþ, a similar approach is advocated, with the caveat that aggressive chemotherapy is not required; most cases spontaneously resolve or complete remission occurs as a consequence of reduction in immunosuppression, with single-agent rituximab being reserved for particularly recalcitrant lesions. Management of DLBCL-CI is more difficult to advise upon. No cases of PAL were submitted to the workshop, and it is likely that few examples of this aggressive lymphoma will be encountered in the future due to the altered management of tuberculosis. Thus, many cases will fall into the category we prefer to call LBP-CI and which the 2016 WHO update proposes to name "incidental DLBCL associated with chronic inflammation." While it is quite possible that R-CHOP may represent overly aggressive treatment for such lesions, there is currently insufficient evidence on the efficacy of alternative approaches to draw meaningful conclusions. However, if
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Image 4 (cont) Friable pieces of thrombus from an aneurysm repair of the descending aorta in a 56-year-old man show clusters of pleomorphic cells with brisk mitotic activity (case SH2015-176, E, x10; and F, x40). An example of a pedunculated fossa ovalis mass showing pleomorphic large clusters of CD20-positive cells associated with fibrin (case SH2015-470, G and H, x40).
R-CHOP is given, the outcome is likely to be excellent provided no mass lesion is present at diagnosis. Given the spectrum of treatment options available, recognition and accurate diagnosis of these entities is essential. For hyperplasias and polymorphic LPDs, appropriate management at an early stage is important in view of the albeit low risk of progression to a more aggressive neoplasm, while it is essential to differentiate MCU, EBVþ and LBP-CI from more aggressive mimics in view of prognostic and, at least for the former, therapeutic considerations. An awareness of the characteristic features as well as the spectrum of morphologies associated with these various disorders, as discussed in the preceding sections, is obviously paramount in accurate diagnosis. In addition, the importance of clinical information, particularly current and prior drug history, and correlation with the pathologic features cannot be overemphasized. A concise summary of EBVþ B-cell proliferations of varied malignant potential can be found in Table 5 . To view full-slide images and case write-ups for selected 2015 SH/EAHP Workshop case numbers mentioned in this article, go to http://bit.ly/2loeRGX. If you are not already signed in as an ASCP member you will be first asked to sign in (or create an ASCP account and sign in).
